Therapy1

PSMA, PRRT, MIBG

2022年9月11日(日) 08:00 〜 20:00 現地会場なし (配信のみ)

+全てマイスケジュールに登録

[WP-20-1] 177Lutetium-labeled PSMA-617 treatment in castration resistant prostate cancer, a ten year experience at UC CHRISTUS Clinical Hospital, Santiago, Chile.

Francisco Aguila、Ignacio Diaz、Ayleen Hiplan、Cristian Waeger、Juan Quintana、Pilar Orellana、Gabriel Castro (Universidad Catolica de Chile)

[WP-20-2] Frequent, significant responses are observed with 177Lu-PSMA treatment in metastatic castration resistant prostate cancer, which associate to improved survival

Jukka Kemppainen^1,2、Aki Kangasmäki ¹、Simona Malaspina^2,3、Kalevi Kairemo¹、Juha Kononen¹、Timo Joensuu¹ (1.Docrates Cancer Center、2.University of Turku、3.Turku University Hospital)

[WP-20-3] Relationship of pretreatment 18F-PSMA PET/CT and organ-based dosimetry in therapy with a novel albumin-binding 177Lu-PSMA radiopharmaceutical

Seunggyun Ha、Sun Ha Boo、Jae Won Min、Joo Hyun O (The Catholic University Of Korea)

[WP-20-4] A Long-term outcome study on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer: A prospective, single-institutional study

Madhav Yadav¹、Sanjana Ballal¹、Chandrasekhar Bal¹、Ranjit Sahoo²、Madhavi Tripathi¹ (1.All India Institute of Medical Sciences, Nuclear Medicine、2.All India Institute of Medical Sciences, Medical Oncology)

[WP-20-5] Safety and Efficacy of Intra-arterial PRRT with Lu-177 DOTATATE in Liver Dominant Metastatic Neuro-endocrine Tumors: Prospective Observational Study

Ameya Puranik、Venkatesh Rangarajan、Nilendu Purandare、Sneha Shah、Archi Agrawal、Suyash Kulkarni、Nitin Shetty、Kunal Gala、Indraja Dev (Tata Memorial Hospital)

[WP-20-6] 131I-mIBG in combination with topotecan in neuroblastoma patients with a poor response to induction chemotherapy (VERITAS)

Gianpaolo Di Santo、martin Jeller、gabriele Kropshofer、Roman Crazzolara、Benjamin Hetzer、Lukas Wirth、Anna Sviridenko、Irene Virgolini (Medical University of Innsbruck)